Elanco Animal Health Incorporated (ELAN)
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
$22.51+1.67%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $11.2B
- Forward P/E
- 17.5
- 52-week range
- $19.40 – $27.98
- 52-week change
- +8.26%
- EPS (trailing)
- −$0.41
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 6, 2026
Fiscal year to Dec 2025
- Revenue
- $4.7B (+6.22%)
- Net income
- −$232M
- Diluted EPS
- −$0.47
- Free cash flow
- $284M
From the company’s annual report on SEC EDGAR.
About Elanco Animal Health Incorporated
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry.
Headquarters: Indianapolis, United States · 9,400 employees · elanco.com